Vancomycin-resistant enterococci overview

Jump to navigation Jump to search

Vancomycin-resistant enterococci Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Vancomycin-Resistant Enterococci from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Vancomycin-resistant enterococci overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Vancomycin-resistant enterococci overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA onVancomycin-resistant enterococci overview

CDC on Vancomycin-resistant enterococci overview

enterococci overview in the news

on Vancomycin-resistant enterococci overview

Directions to Hospitals Treating Vancomycin-resistant enterococci

Risk calculators and risk factors for Vancomycin-resistant enterococci overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

Enterococci are bacteria that are normally present in the human intestines and in the female genital tract and are often found in the environment. These bacteria can sometimes cause infections. Vancomycin is an antibiotic that is often used to treat infections caused by enterococci. In some instances, enterococci have become resistant to this drug and thus are called vancomycin-resistant enterococci (VRE). Most VRE infections occur in hospitals.

Historical Perspective

Vancomycin-resistant enterococci (VRE), first reported in Europe in 1988, are emerging as a global threat to public health. The incidence of VRE infection and colonization among hospitalized patients has increased rapidly in the last 7 years. From 1989, the year VRE was first identified in the United States, through 1993, the proportion of enterococcal isolates resistant to vancomycin reported to the National Nosocomial Infections Surveillance System increased 20-fold.

Risk Factors

Prior treatment with antibiotics is common in nearly all patients colonized or infected with MDR enterococci. Clindamycin, cephalosporin,aztreonam,ciprofloxacin, aminoglycoside, and metronidazole use is equally or more often associated with colonization or infection with MDR enterococci than vancomycin use. Other risk factors include prolonged hospitalization, high severity of illness score, intraabdominal surgery, renal insufficiency, enteral tube feedings, and exposure to specific hospital units, nurses, or contaminated objects and surfaces within patient-care areas.

Treatment

Medical Therapy

Most VRE infections can be treated with antibiotics other than vancomycin. The treatment of VRE is determined by laboratory testing to determine which antibiotics are effective. For persons who get VRE infections and have urinary catheters, removal of the catheter when it is no longer needed can help getting rid of the infection. People who are colonized (bacteria are present, but have no symptoms of an infection) with VRE do not usually need treatment.

References

Template:WH Template:WS